Strides Pharma Science Ltd. has recently published its consolidated financial results for the third quarter of the fiscal year 2025, reporting strong growth across key financial parameters.
The company recorded revenue of INR 11,537 million, reflecting a 14.6 percent year-on-year increase. The gross margin stood at INR 6,735 million, marking a 25.1 percent rise compared to the same quarter last year. EBITDA grew by 46.9 percent year-on-year to INR 2,103 million, with an EBITDA margin of 18.2 percent, up by 401 basis points. The company reported a net profit of INR 900 million for the quarter, with an earnings per share of INR 9.56.
The US business contributed USD 73 million in revenue, reflecting a 13.7 percent year-on-year growth. For the first nine months of FY25, Strides reported total revenue of INR 33,749 million, a 17.3 percent increase compared to the same period in the previous year.
EBITDA for the nine-month period stood at INR 5,849 million, up by 43.3 percent. The US segment achieved USD 214 million in revenue for the nine-month period, growing by 21.3 percent year-on-year, and remains on track to achieve its full-year revenue outlook of USD 275 million to USD 290 million following the demerger of the Softgel business.
Arun Kumar, Founder & Executive Chairperson, and Badree Komandur, MD & Group CEO, commented on the performance and said, “We are pleased to report strong YTD results showcasing a YoY improvement across all key metrics of growth, profitability and efficiency. Our 9MFY25 revenue increased by 17.3 percent YoY and EBITDA grew by 43.3 percent YoY despite the demerger of high margin Softgel business. For 9MFY25, the US business recorded a revenue of USD 214m, a growth of 21.3 percent YoY, and is well on track to achieve the FY25 outlook of USD 275m- USD 290m, post-demerger. Additionally, we are proud to have debuted with an outstanding ESG rating of 76/100 in the S&P Global’s CSA, 2024. We are placed significantly ahead of our peers in the first year of ESG evaluation, underscoring our unwavering commitment to sustainability and the strength of our processes and governance. Looking ahead, we remain focused on executing our strategies to deliver superior business outcomes and drive long-term value for our stakeholders.”
Headquartered in Bengaluru, India, Strides is a global pharmaceutical company listed on the BSE and NSE. It operates in regulated markets with an "in Africa for Africa" strategy and provides institutional business services for donor-funded markets. The company has manufacturing facilities in India, Italy, Kenya, and the United States and specializes in manufacturing complex pharmaceutical products sold in over 100 countries.
Last news about this category
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy